Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients

Leukemia

Volumn 23, Issue 11, 2009, Pages 2139-2146

  Colucci, S ^a   Brunetti, G ^a   Mori, G ^b   Oranger, A ^a   Centonze, M ^a   Mori, C ^a   Cantatore, F P ^b   Tamma, R ^a   Rizzi, R ^a   Liso, V ^a   Zallone, A ^a   Grano, M ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CD14 ANTIGEN; DECOY RECEPTOR 3; FAS LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE DISEASE; CANCER CELL CULTURE; CELL COUNT; CELL MATURATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA FRAGMENTATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MONOCYTE; MULTIPLE MYELOMA; OSTEOCLAST; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; T LYMPHOCYTE; UPREGULATION;

AGED; BONE MARROW CELLS; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; FAS LIGAND PROTEIN; HUMANS; MIDDLE AGED; MONOCYTES; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOLYSIS; PLASMA CELLS; RANK LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; STROMAL CELLS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70450240910     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.136     Document Type: Article

References (35)

1. Edwards CM, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone 2008; 42: 1007-1013.
2. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
3. Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G et al T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: The role of the OPG/ TRAIL interaction. Blood 2004; 104: 3722-3730.
4. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: A potential role in multiple myeloma bone disease. Blood 2002; 100: 4615-4621.
5. Miranda-Carús ME, Benito-Miguel M, Balsa A, Cobo-Ibáñez T, Pérez de Ayala C, Pascual-Salcedo D et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006; 54: 1151-1164.
6. Brunetti G, Colucci S, Pignataro P, Coricciati M, Mori G, Cirulli N et al. T cells support the osteoclastogenesis in an in vitro model derived from human periodontitis patients. J Periodontol 2005; 76: 1675-1680.
7. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Quarta L et al. Lymphocytes and synovial fluid fibroblasts support the osteoclastogenesis through RANKL, TNF-alpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol 2007; 212: 47-55.
8. Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O et al Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 2005; 19: 228-230.
9. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-1488.
10. Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005; 202: 589-595.
11. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNF alpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002; 143: 1108-1118.
12. Abu-Amer Y, Erdmann J, Kollias G, Alexopoulou L, Ross FP, Teitelbaum SL. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000; 275: 27307-27310.
13. Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 2004; 11 (Suppl 1): S97-S107.
14. Tang CH, Hsu TL, Lin WW, Lai MZ, Yang RS, Hsieh SL et al. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J Biol Chem 2007; 282: 2346-2354.
15. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P et al Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703.
16. Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P et al Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 2001; 61: 2759-2765.
17. Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci USA 2000; 97: 1230-1235.
18. Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M et al. Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett 2000; 160: 89-97.
19. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BX. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999; 274: 13733-13736.
20. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16: 479-492.
21. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
22. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
23. Connor JP, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol 2008; 111: 330-335.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: E45.
25. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P et al. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis 2007; 12: 1623-1632.
26. Shen HW, Gao SL, Wu YL, Peng SY. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 2005; 11: 5926-5930.
27. Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, Nakajima S et al. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 2003; 106: 17-25.
28. Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Fujimura T et al Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol 2001; 18: 311-316.
29. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17 1675-1687.
30. Hayashi S, Miura Y, Nishiyama T, Mitani M, Tateishi K, Sakai Y et al Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 2007; 56: 1067-1075.
31. Strand S, Galle PR. Immune evasion by tumours: Involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998; 4: 63-68.
32. Chou CT, Yang JS, Lee MR. Apoptosis in rheumatoid arthritis - expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. J Pathol 2001; 193: 110-116.
33. Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C et al. CC-Chemokine ligand 20/macrophage inflammatory protein-3alpha and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 2008; 68: 6840-6850.
34. El Hajj Dib I, Mélanie G, Valery S, Romuald M, Michel B, Kamel S. Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis. Leuk Res 2008; 2: 1279-1287.
35. Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum 2006; 54: 1451-1462.